Clinical management of aplastic anemia

Research output: Contribution to journalReview article

Abstract

Acquired aplastic anemia is a potentially fatal bone marrow failure disorder that is characterized by pancytopenia and a hypocellular bone marrow. Hematopoietic stem-cell transplantation or bone marrow transplantation (BMT) is the treatment of choice for young patients who have a matched sibling donor. Immunosuppression with either anti-thymocyte globulin and cyclosporine or high-dose cyclophosphamide is an effective therapy for patients who are not suitable BMT candidates owing to age or lack of a suitable donor. Results of BMT from unrelated and mismatched donors are improving, but presently this treatment option is best reserved for those patients who do not respond, relapse or develop secondary clonal disorders following immunosuppressive therapy. Efforts are currently underway to both improve immunosuppressive regimens and to expand the application of BMT.

Original languageEnglish (US)
Pages (from-to)221-230
Number of pages10
JournalExpert review of hematology
Volume4
Issue number2
DOIs
StatePublished - Apr 1 2011

Keywords

  • anti-thymocyte globulin
  • aplastic anemia
  • bone marrow failure
  • bone marrow transplantation
  • cyclosporine
  • hematopoietic stem-cell transplantation
  • high-dose cyclophosphamide
  • paroxysmal nocturnal hemoglobinuria

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Clinical management of aplastic anemia'. Together they form a unique fingerprint.

  • Cite this